Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term real-world safety study of Skyclarys in Friedreich's ataxia
NL-OMON61239Phase 4Not yet recruiting
- Sponsor
- Biogen
- Start
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of omaveloxolone in Friedreich ataxia (FA) (2 cohorts), sponsored by Biogen. Primary endpoints: Description and incidence of drug-induced liver injury adverse events, Description and incidence of congestive heart failure adverse events and 1 more. Planned start Apr 2027; status: not yet recruiting.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NL-OMON61239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61239.